PL2717692T3 - Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych - Google Patents

Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Info

Publication number
PL2717692T3
PL2717692T3 PL12796691T PL12796691T PL2717692T3 PL 2717692 T3 PL2717692 T3 PL 2717692T3 PL 12796691 T PL12796691 T PL 12796691T PL 12796691 T PL12796691 T PL 12796691T PL 2717692 T3 PL2717692 T3 PL 2717692T3
Authority
PL
Poland
Prior art keywords
tetrahydrocannabinol
fibrotic diseases
treating fibrotic
oic acids
oic
Prior art date
Application number
PL12796691T
Other languages
English (en)
Inventor
Robert B. Zurier
Enrico Selvi
Original Assignee
Corbus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals, Inc. filed Critical Corbus Pharmaceuticals, Inc.
Publication of PL2717692T3 publication Critical patent/PL2717692T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12796691T 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych PL2717692T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161493435P 2011-06-04 2011-06-04
US13/485,044 US20120309820A1 (en) 2011-06-04 2012-05-31 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
PCT/US2012/040380 WO2012170290A1 (en) 2011-06-04 2012-06-01 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP12796691.9A EP2717692B1 (en) 2011-06-04 2012-06-01 Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases

Publications (1)

Publication Number Publication Date
PL2717692T3 true PL2717692T3 (pl) 2020-06-15

Family

ID=47262154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12796691T PL2717692T3 (pl) 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Country Status (8)

Country Link
US (3) US20120309820A1 (pl)
EP (2) EP2717692B1 (pl)
DK (1) DK2717692T3 (pl)
ES (1) ES2753639T3 (pl)
HU (1) HUE047419T2 (pl)
PL (1) PL2717692T3 (pl)
PT (1) PT2717692T (pl)
WO (1) WO2012170290A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
JP6307290B2 (ja) * 2013-03-06 2018-04-04 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
CA3010861A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of cannabinoids
US20190060300A1 (en) * 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
EP3448377A4 (en) * 2016-04-29 2019-12-25 Corbus Pharmaceuticals, Inc. METHODS FOR THE TREATMENT OF AN INFECTION
KR20210043494A (ko) * 2018-05-31 2021-04-21 코버스 파마수티컬스, 아이엔씨. 칸나비노이드 및 그의 용도
WO2020018554A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Methods of treating renal disease
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
WO2021239863A1 (en) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
EP4161929A1 (en) 2020-06-08 2023-04-12 Mission Therapeutics Limited 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis

Also Published As

Publication number Publication date
EP2717692A1 (en) 2014-04-16
PT2717692T (pt) 2019-11-18
HUE047419T2 (hu) 2020-04-28
ES2753639T3 (es) 2020-04-13
US20120309820A1 (en) 2012-12-06
US20160367518A1 (en) 2016-12-22
DK2717692T3 (da) 2019-11-11
US20180116999A1 (en) 2018-05-03
EP3620211A1 (en) 2020-03-11
WO2012170290A1 (en) 2012-12-13
EP2717692B1 (en) 2019-08-07
EP2717692A4 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
GB2487248B (en) Water treatment
GB2487246B (en) Water treatment
ZA201400435B (en) Therapeutic methods
GB2487247B (en) Water treatment
SG11201400256PA (en) Water treatment method
GB201108797D0 (en) Surface treatment method
ZA201308176B (en) Therapeutic treatment
GB201121950D0 (en) Treatment process
GB2487249B (en) Water treatment
ZA201308117B (en) Avian-based treatment
GB201105523D0 (en) Treatment method
GB201100455D0 (en) Methods relating to treatment
GB201105056D0 (en) Treatment process
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102269D0 (en) Treatment
GB201102273D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102263D0 (en) Treatment
GB201102284D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102274D0 (en) Treatment